Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Accured Expenses: 2017-2024

Historic Change in Accured Expenses for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $17.0 million.

  • BridgeBio Pharma's Change in Accured Expenses rose 1396.09% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.6 million, marking a year-over-year increase of 1333.37%. This contributed to the annual value of $17.0 million for FY2024, which is 117.71% up from last year.
  • As of FY2024, BridgeBio Pharma's Change in Accured Expenses stood at $17.0 million, which was up 117.71% from $7.8 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Change in Accured Expenses ranged from a high of $17.0 million in FY2024 and a low of -$7.7 million during FY2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was $7.8 million (2023), whereas its average is $5.7 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 154.57% in 2022, then spiked by 200.94% in 2023.
  • Over the past 5 years, BridgeBio Pharma's Change in Accured Expenses (Yearly) stood at $8.6 million in 2020, then spiked by 64.91% to $14.2 million in 2021, then tumbled by 154.57% to -$7.7 million in 2022, then soared by 200.94% to $7.8 million in 2023, then surged by 117.71% to $17.0 million in 2024.